Improvement in survival after paraquat ingestion following introduction of a new formulation in Sri Lanka
dc.contributor.author | Wilks, M.F. | en |
dc.contributor.author | Fernando, R. | en |
dc.contributor.author | Ariyananda, P.L. | en |
dc.contributor.author | Eddleston, M. | en |
dc.contributor.author | Berry, D.J. | en |
dc.contributor.author | Tomenson, J.A. | en |
dc.contributor.author | Buckley, N.A. | en |
dc.contributor.author | Jayamanne, S. | en |
dc.contributor.author | Gunnell, D. | en |
dc.contributor.author | Dawson, A. | en |
dc.date.accessioned | 2016-01-28T09:18:08Z | en |
dc.date.available | 2016-01-28T09:18:08Z | en |
dc.date.issued | 2008 | en |
dc.description | Indexed in MEDLINE | en_US |
dc.description.abstract | BACKGROUND: Pesticide ingestion is a common method of self-harm in the rural developing world. In an attempt to reduce the high case fatality seen with the herbicide paraquat, a novel formulation (INTEON) has been developed containing an increased emetic concentration, a purgative, and an alginate that forms a gel under the acid conditions of the stomach, potentially slowing the absorption of paraquat and giving the emetic more time to be effective. We compared the outcome of paraquat self-poisoning with the standard formulation against the new INTEON formulation following itsintroduction into Sri Lanka. METHODS AND FINDINGS: Clinical data were prospectively collected on 586 patients with paraquat ingestion presenting to nine large hospitals across Sri Lanka with survival to 3 mo as the primary outcome. The identity of the formulation ingested after October 2004 was confirmed by assay of blood or urine samples for a marker compound present in INTEON. The proportion of known survivors increased from 76/297 with the standardformulation to 103/289 with INTEON ingestion, and estimated 3-mo survival improved from 27.1% to 36.7% (difference 9.5%; 95% confidence interval [CI] 2.0%-17.1%; p = 0.002, log rank test). Cox proportional hazards regression analyses showed an approximately 2-fold reduction in toxicity for INTEON compared to standard formulation. A higher proportion of patients ingesting INTEON vomited within 15 min (38% with the originalformulation to 55% with INTEON, p < 0.001). Median survival time increased from 2.3 d (95% CI 1.2-3.4 d) with the standard formulation to 6.9 d (95% CI 3.3-10.7 d) with INTEON ingestion (p = 0.002, log rank test); however, in patients who did not survive there was a comparatively smaller increase in median time to death from 0.9 d (interquartile range [IQR] 0.5-3.4) to 1.5 d (IQR 0.5-5.5); p = 0.02. CONCLUSIONS: The survey has shown that INTEON technology significantly reduces the mortality of patients following paraquat ingestion and increases survival time, most likely by reducing absorption. Comment in : New formulation of paraquat: a step forward but in the wrong direction. [PLoS Med. 2008] | en_US |
dc.identifier.citation | PLoS Medicine.2008;5(2):e49 | en_US |
dc.identifier.issn | 1549-1277 (Print) | |
dc.identifier.issn | 1549-1676 (Electronic) | |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/11439 | |
dc.language.iso | en_US | en_US |
dc.publisher | Public Library of Science | en_US |
dc.subject | Improvement in survival | en_US |
dc.title | Improvement in survival after paraquat ingestion following introduction of a new formulation in Sri Lanka | en_US |
dc.type | Article | en_US |